Sponsor content
10 result(s) found, displaying 1 to 10
-
Prescription medicine decision summarySlenyto has been approved for the treatment of insomnia in children and adolescents with neurogenetic disorders and/or attention-deficit hyperactivity disorder (ADHD).
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Alprostadil
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Lurasidone hydrochloride
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Melatonin